奥曲肽联合地芬诺酯对急性胰腺炎的治疗效果及对血清Ghrelin、PCT、IL-6 的影响

Therapeutic effect of Octreotide combined with Diphenoxylate on acute pancreatitis and its effect on serum Ghrelin, PCT and IL-6

摘要:

目的 探讨奥曲肽联合地芬诺酯对急性胰腺炎的治疗效果及对血清生长素（Ghrelin）、降钙素 原（PCT）、白细胞介素6（IL-6）的影响。方法 96 例急性胰腺炎患者按随机数表法分为对照组和试验组，每 组48 例。对照组接受奥曲肽治疗，试验组基于对照组加地芬诺酯，两组均持续治疗7 d。比较两组临床疗效， 临床指标缓解时间，血清Ghrelin、PCT、IL-6 表达水平及不良反应。结果 试验组和对照组总有效率分别为 95.83% 和79.17%，差异有统计学意义（P <0.05）。试验组临床指标缓解时间均短于对照组，差异有统计学意义 （P <0.05）。试验组和对照组血清Ghrelin 分别为（155.92±20.03）和（189.11±20.00）ng/L、PCT 分别为（0.62±0.09） 和（0.97±0.14）μg/L、IL-6 分别为（9.50±1.31）和（14.39±1.84）ng/L，差异有统计学意义（P <0.05）。两组 均有厌食、腹痛及呕吐发生，试验组和对照组不良反应率分别为20.83% 和25.00%，差异无统计学意义（χ2= 0.235，P =0.627）。结论 奥曲肽联合地芬诺酯对急性胰腺炎患者的治疗效果优于单用奥曲肽者，能够降低血 清Ghrelin、PCT、IL-6 水平，利于患者恢复。

Abstract:

Objective To discuss the therapeutic effect of Octreotide combined with Diphenoxylate for acute pancreatitis and influence on serum Ghrelin, PCT and IL-6. Methods Totally 96 patients with acute pancreatitis were randomly divided into control group (n = 48) and treatment group (n = 48). The control group received Octreotide therapy, subcutaneous injection of Octreotide, (0.1 mg, qd); the treatment group was based on the control group plus Diphenoxylate, and both groups lasted for 7 days. Clinical efficacy, clinical indicator remission time, expression levels and side effects of serum Ghrelin, PCT and IL-6 were compared between the groups. Results Total effective rates of treatment group and control group were 95.83% and 79.17%, respectively; the difference was statistically significant (P < 0.05). Clinical indicator remission time of the treatment group was shorter than the control group, the difference was statistically significant (P < 0.05). Serum Ghrelin of treatment group and control group was (155.92 ± 20.03) ng/ L and (189.11 ± 20.00) ng/L, respectively; PCT was (0.62 ± 0.09) μg/L and (0.97 ± 0.14) μg/L, respectively; IL-6 was (9.50 ± 1.31)μg/L and (14.39 ± 1.84) ng/L, respectively; the differences were statistically significant (P < 0.05). Anorexia, abdominal pain and vomiting occurred in both groups, adverse reaction rate was 20.83% and 25.00%, respectively, there was no statistically significant difference (χ2 = 0.235, P = 0.627). Conclusion The therapeutic effect of Octreotide combined with Diphenoxylate on acute pancreatitis is better than the Octreotide only, which can reduce levels of serum Ghrelin, PCT and IL-6, and is better for patient's habilitation.